Speaker Profile
Ph.D., CEO, IntoDNA
Biography
Magda founded intoDNA with a mission to make STRIDE the new standard in DNA damage analysis and enable DNA break detection at a new precision. She has authored the publication and the patent on DNA damage analysis with STRIDE. With more than a decade of research experience in biophysics and cell biology, she leads intoDNA and the STRIDE technology into new business verticals to support consistently growing numbers of customers in diagnosing DNA damage in yet new areas. Magda earned her PhD in Cell Biophysics from Jagiellonian University and was a visiting PhD student at UC Davis, Cold Spring Harbor Laboratory and UMass Medical School.
Talk
AI-enabled functional biomarkers of replication stress and DNA repair
We present a proprietary suite of functional assays and AI powered digital pathology software that quantify replication stress, DNA damage, and repair activity in situ for precision oncology.
AI and Data Sciences Showcase:
IntoDNA
intoDNA is a precision medicine company pioneering functional biomarkers that directly measure DNA damage repair pathway activity. Its proprietary STRIDE® platform delivers ultra-sensitive, in situ functional insight not inferable from genomics alone. STRIDE supports biopharma research today and is advancing toward diagnostic and companion diagnostic applications, including dSTRIDE™-HR for functional HRD assessment to improve patient stratification and accelerate drug development.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
